Key Takeaways TEM launched xM liquid biopsy to monitor ICI therapy response in solid tumors. Tempus AI introduced Loop, an AI platform combining RWD and CRISPR screens. Development of xH signals TEM's move into WGS to guide hematologic cancer treatment choice.Tempus AI (TEM) continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay to detect molecular response to immune-checkpoin ...

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing Early access via large-scale clinical study to establish the validity and utility of the FirstGeneTM screen SALT LAKE CITY, June 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced early access to the FirstGeneTM Multiple Prenatal Screen. The company will begin a large study that will s ...